|
Reason
|
Home follow-upa
|
Clinic follow-upb
|
P-valuec
|
|---|
|
N=986
|
(%)
|
N=2932
|
(%)
|
|---|
|
Adverse reaction
|
24
|
(2.4)
|
105
|
(3.6)
|
0.24
|
|
Abnormal liver enzymesd
|
3
|
(0.3)
|
40
|
(1.4)
|
0.02
|
|
INH –related hepatitis
e
|
1
|
(0.1)
|
23
|
(0.8)
|
0.06
f
|
|
Rash
|
7
|
(0.7)
|
30
|
(1.0)
|
0.58
|
|
Other symptomsg
|
14
|
(1.4)
|
35
|
(1.2)
|
0.58
|
|
Refused/Losth
|
75
|
(7.6)
|
680
|
(23.2)
|
<0.001
|
-
aHome-based follow-up with community health workers and public health nurses.
-
bClinic-based follow-up.
-
cAnalysis by chi-square or Fisher’s exact test, adjusted for multiple comparisons.
-
dAny abnormality of liver enzymes associated with treatment discontinuation.
-
eSubset of patients with abnormal liver enzymes with isoniazid-related hepatitis, based on chart review.
-
fp-value for INH-related hepatitis only.
-
gAny other intolerable symptom that necessitated treatment discontinuation such as headache, dizziness, fatigue, among others.
-
hRefused to continue treatment or were lost to follow-up.
